Equities

AbbVie Inc

0QCV:LSE

AbbVie Inc

  • Price (USD)161.83
  • Today's Change0.26 / 0.16%
  • Shares traded1.33k
  • 1 Year change10.13%
  • Beta--
Data delayed at least 20 minutes, as of May 15 2024 14:30 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year AbbVie Inc's revenues fell -6.44% from 58.05bn to 54.32bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 11.84bn to 4.86bn, a -58.91% decrease.
Gross margin66.30%
Net profit margin11.04%
Operating margin23.50%
Return on assets4.24%
Return on equity55.92%
Return on investment5.61%
More ▼

Cash flow in USDView more

In 2023, AbbVie Inc increased its cash reserves by 39.27%, or 3.61bn. The company earned 22.84bn from its operations for a Cash Flow Margin of 42.05%. In addition the company used 2.01bn on investing activities and also paid 17.22bn in financing cash flows.
Cash flow per share8.29
Price/Cash flow per share19.43
Book value per share4.53
Tangible book value per share-49.64
More ▼

Balance sheet in USDView more

AbbVie Inc has a Debt to Total Capital ratio of 90.19%, a lower figure than the previous year's 446.68%.
Current ratio0.9362
Quick ratio0.8339
Total debt/total equity9.24
Total debt/total capital0.9019
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)4.08%
Div growth rate (5 year)10.52%
Payout ratio (TTM)181.01%
EPS growth(5 years)-6.05
EPS (TTM) vs
TTM 1 year ago		-20.78
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.